BRPI0912564A2 - inibidores de jnk - Google Patents

inibidores de jnk

Info

Publication number
BRPI0912564A2
BRPI0912564A2 BRPI0912564A BRPI0912564A BRPI0912564A2 BR PI0912564 A2 BRPI0912564 A2 BR PI0912564A2 BR PI0912564 A BRPI0912564 A BR PI0912564A BR PI0912564 A BRPI0912564 A BR PI0912564A BR PI0912564 A2 BRPI0912564 A2 BR PI0912564A2
Authority
BR
Brazil
Prior art keywords
jnk inhibitors
jnk
inhibitors
Prior art date
Application number
BRPI0912564A
Other languages
English (en)
Inventor
Bartolome Arzeno Humberto
Patrick Dunn James
Michael Goldstein David
Gong Leyi
Han Xiaochun
Heather Hogg Joan
Jahangir Alam
Solang Palmer Wylie
Carol Reuter Deborah
Silva Tania
Tivitmahaisoon Percharee
Alejandra Trejo-Martin Teresa
Wu Shao-Yong
Original Assignee
F. Hoffman-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffman-La Roche Ag filed Critical F. Hoffman-La Roche Ag
Publication of BRPI0912564A2 publication Critical patent/BRPI0912564A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0912564A 2008-05-16 2009-05-06 inibidores de jnk BRPI0912564A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5389608P 2008-05-16 2008-05-16
PCT/EP2009/055443 WO2009138340A1 (en) 2008-05-16 2009-05-06 Inhibitors of jnk

Publications (1)

Publication Number Publication Date
BRPI0912564A2 true BRPI0912564A2 (pt) 2019-09-24

Family

ID=40937466

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912564A BRPI0912564A2 (pt) 2008-05-16 2009-05-06 inibidores de jnk

Country Status (18)

Country Link
US (1) US8183254B2 (pt)
EP (1) EP2283009B1 (pt)
JP (1) JP5329648B2 (pt)
KR (1) KR101368079B1 (pt)
CN (1) CN102015689B (pt)
AR (1) AR071789A1 (pt)
AU (1) AU2009248233A1 (pt)
BR (1) BRPI0912564A2 (pt)
CA (1) CA2722158A1 (pt)
CL (1) CL2009001192A1 (pt)
ES (1) ES2392788T3 (pt)
IL (1) IL208916A0 (pt)
MX (1) MX2010012249A (pt)
PE (1) PE20091968A1 (pt)
RU (1) RU2504545C2 (pt)
TW (1) TW200948804A (pt)
WO (1) WO2009138340A1 (pt)
ZA (1) ZA201007178B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012030814A2 (pt) * 2010-06-04 2019-09-24 Hoffmann La Roche inibidores de jnk
CA2799328C (en) * 2010-06-04 2018-02-20 Humberto Bartolome Arzeno 2 -amino- pyrimidine derivatives useful as inhibitors of jnk
ES2985135T3 (es) 2014-12-18 2024-11-04 Harvard College Procedimientos para generar células ß derivadas de células madre y usos de las mismas
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1206265B1 (en) * 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
DE60318567T2 (de) * 2002-04-25 2009-02-19 Laboratoires Serono S.A., Coinsins Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
KR101177729B1 (ko) * 2006-09-08 2012-09-07 에프. 호프만-라 로슈 아게 벤조트리아졸 키나아제 조절제
BRPI0720003A2 (pt) * 2006-12-08 2018-09-18 Hoffmann La Roche pirimidinas substituídas e seu uso como moduladores de jnk

Also Published As

Publication number Publication date
JP2011520824A (ja) 2011-07-21
CN102015689A (zh) 2011-04-13
IL208916A0 (en) 2011-01-31
ES2392788T3 (es) 2012-12-13
EP2283009A1 (en) 2011-02-16
EP2283009B1 (en) 2012-08-29
WO2009138340A1 (en) 2009-11-19
ZA201007178B (en) 2013-03-27
AR071789A1 (es) 2010-07-14
US20090318484A1 (en) 2009-12-24
US8183254B2 (en) 2012-05-22
MX2010012249A (es) 2010-12-06
RU2504545C2 (ru) 2014-01-20
CL2009001192A1 (es) 2010-08-13
CN102015689B (zh) 2014-01-08
TW200948804A (en) 2009-12-01
JP5329648B2 (ja) 2013-10-30
KR101368079B1 (ko) 2014-03-14
CA2722158A1 (en) 2009-11-19
PE20091968A1 (es) 2010-01-15
KR20100137567A (ko) 2010-12-30
AU2009248233A1 (en) 2009-11-19
RU2010151475A (ru) 2012-06-27

Similar Documents

Publication Publication Date Title
FIC20250022I1 (fi) Atetsolitsumabi
CY2020024I2 (el) Αναστολεiς βητα-λακταμασων
NL300965I2 (nl) Patisiran
NL300961I2 (nl) Erenumab
CY2017016I1 (el) Αναστολεις πρωτεασωματος
FIC20170031I1 (fi) alirokumabi
EP2305306A4 (en) NEURO INVASION INHIBITOR
DK2335370T3 (da) Organ-på-en-chip-anordning
DK2370462T3 (da) Glucagon-analoger
DK2342317T3 (da) Hængende-dråbe-plade
BRPI0907376A2 (pt) Fotobiorretador
FIC20240018I1 (fi) Vamoroloni
BRPI0918564A2 (pt) inibidores
DK2379557T3 (da) Aminopyrazol-forbindelse
DK2300238T3 (da) Skyggebillede-sikkerhedstræk
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
EP2257170A4 (en) TETRAHYDROFUROPYRIDONE
ES1067341Y (es) Dispositivo perforador-fijador
EP2339366A4 (en) DEVICE FOR OPTICAL DISTANCE MEASUREMENT
DE112009001946A5 (de) Mobelauszugsführung
BR112012003059A2 (pt) inibidores de jnk
FI20080325A0 (fi) Pihkaliuos
FIU20080263U0 (fi) Suunhoitovalmiste
ES1068331Y (es) Dispositivo identificador
ES1068149Y (es) Dispositivo salvavidas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.